Established in August 2014, Tonghua Anrate Biopharmaceutical Co., Ltd. (referred to as Anrate) embarked on a groundbreaking mission as a pioneer in the field of biopharmaceuticals. Under the visionary guidance of national initiatives such as the "the 14th Five-Year Plan" for key national research and development plans, and the "the 12th Five-Year Plan" for major new drug development, Anrate spearheaded projects aimed at revolutionizing the production of therapeutic adjunctive medical proteins. At the forefront of innovation, Anrate assumed leadership roles in key projects such as the "Industrial Demonstration of Therapeutic Adjunctive Medical Proteins such as Albumin" and the "Development of Injection-Grade Recombinant Human Albumin". Recognized for our contributions, Anrate has received commendations from Party and state leaders, along with unwavering support from local governments.
Years of dedicated effort have culminated in the establishment of a comprehensive recombinant protein drug research and development system. This system encompasses gene editing, cell chassis screening and cultivation, product separation and purification, and rigorous detection protocols. By overturning traditional production methodologies, Anrate has achieved remarkable milestones in industrialization scale, production efficiency, and product purity, positioning ourselves as a beacon of innovation on the global stage.
In 2018, we celebrated the successful launch of our first production line, setting a new benchmark with the largest global albumin biopharmaceutical production scale at the time, boasting an annual output of 5 tons. Looking ahead, we are poised for even greater achievements. By 2024, our production base will expand to accommodate a staggering 100-ton capacity, catering to the growing demand for recombinant human albumin raw materials and formulations. In March 2024, we achieved yet another milestone with the completion and licensing of a 50-ton recombinant human albumin raw material and reagent production line. As we continue to push boundaries, our vision extends to 2026, where we will invest in a nationwide 200-ton production system, further solidifying our commitment to advancing biopharmaceutical manufacturing in China.
Anrate's dedication to innovation extends beyond production processes. We have championed the adoption of domestically produced core biopharmaceutical equipment, achieving a localization rate of over 90%. This not only strengthens the domestic manufacturing ecosystem but also ensures our ability to address critical challenges, such as viral and heterologous material contaminations in human blood. By mitigating biosecurity risks and resolving supply shortages, Anrate is reshaping the landscape of biopharmaceutical manufacturing, paving the way for a healthier future."
中文